MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2024: Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by 2035, Predicts DelveInsight
Akeso Inc. (HKEX Code: 9926.HK, “Akeso”)
Organization & Developments: Akeso
Parents
Akeso Inc. (HKEX Code: 9926.HK, “Akeso”)
Children
*Akeso is internally working on a robust pipeline of over 30 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease, and other major therapeutic areas.
2022: Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
2024: Akeso's Bispecific Antibody Ivonescimab Bests Keytruda in PD-L1-Expressing NSCLC
2025: Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US competition_www.scmp.com
2026: ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Jumps
Finance & Acquisitions: Akeso
Key People: Akeso